Iteos Therapeutics Performance
| ITOSDelisted Stock | USD 10.15 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of -0.0417, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Iteos Therapeutics are expected to decrease at a much lower rate. During the bear market, Iteos Therapeutics is likely to outperform the market. Iteos Therapeutics right now retains a risk of 0.0%. Please check out Iteos Therapeutics total risk alpha, as well as the relationship between the downside variance and day median price , to decide if Iteos Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Iteos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Iteos Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 251.5 M | |
| Total Cashflows From Investing Activities | -131.2 M |
Iteos |
Iteos Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,015 in Iteos Therapeutics on November 9, 2025 and sell it today you would earn a total of 0.00 from holding Iteos Therapeutics or generate 0.0% return on investment over 90 days. Iteos Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Iteos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iteos Therapeutics Target Price Odds to finish over Current Price
The tendency of Iteos Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 10.15 | 90 days | 10.15 | about 36.22 |
Based on a normal probability distribution, the odds of Iteos Therapeutics to move above the current price in 90 days from now is about 36.22 (This Iteos Therapeutics probability density function shows the probability of Iteos Stock to fall within a particular range of prices over 90 days) .
Iteos Therapeutics Price Density |
| Price |
Predictive Modules for Iteos Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Iteos Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Iteos Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Iteos Therapeutics is not an exception. The market had few large corrections towards the Iteos Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Iteos Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Iteos Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | -0.04 | |
σ | Overall volatility | 0.09 | |
Ir | Information ratio | -0.13 |
Iteos Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Iteos Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Iteos Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Iteos Therapeutics is not yet fully synchronised with the market data | |
| Iteos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (134.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (98.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors |
Iteos Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Iteos Stock often depends not only on the future outlook of the current and potential Iteos Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Iteos Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.5 M | |
| Cash And Short Term Investments | 494.6 M |
Iteos Therapeutics Fundamentals Growth
Iteos Stock prices reflect investors' perceptions of the future prospects and financial health of Iteos Therapeutics, and Iteos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iteos Stock performance.
| Return On Equity | -0.35 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (61.62 M) | |||
| Shares Outstanding | 44.21 M | |||
| Price To Earning | 50.50 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 12.78 X | |||
| Revenue | 35 M | |||
| EBITDA | (121.82 M) | |||
| Cash And Equivalents | 791.86 M | |||
| Cash Per Share | 22.26 X | |||
| Total Debt | 5.1 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 12.90 X | |||
| Cash Flow From Operations | (98.18 M) | |||
| Earnings Per Share | (4.73) X | |||
| Total Asset | 686.98 M | |||
| Retained Earnings | (9.78 M) | |||
About Iteos Therapeutics Performance
Assessing Iteos Therapeutics' fundamental ratios provides investors with valuable insights into Iteos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Iteos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.Things to note about Iteos Therapeutics performance evaluation
Checking the ongoing alerts about Iteos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iteos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iteos Therapeutics is not yet fully synchronised with the market data | |
| Iteos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35 M. Net Loss for the year was (134.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Iteos Therapeutics currently holds about 791.86 M in cash with (98.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 90.0% of the company shares are owned by institutional investors |
- Analyzing Iteos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iteos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Iteos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iteos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iteos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iteos Therapeutics' stock. These opinions can provide insight into Iteos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Iteos Stock
If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |